BioMedNewsBreaks

ThursdayNov 30, 2023 12:32 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), Celly Nu Complete Plan of Arrangement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) and Celly Nutrition Corp. (“Celly Nu”) today announced the closing of the previously proposed distribution of a portion of FSD Pharma’s holdings of common shares of Celly Nu (“Celly Nu shares”) to certain securityholders of FSD Pharma through a statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the “plan of arrangement”), per the arrangement agreement dated Oct. 4, 2023. As detailed in FSD Pharma’s press release dated Nov. 21, 2023, the record date of the plan of arrangement was set at Nov. 28, 2023. On Nov. 29,…

Continue Reading

WednesdayNov 29, 2023 2:23 pm

BioMedNewsBreaks – Tharimmune Inc. (NASDAQ: THAR) Announces Pricing of $10M Public Offering

Tharimmune (NASDAQ: THAR), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory and oncologic conditions, has announced the pricing of an underwritten public offering of 10,000,000 shares of common stock (or pre-funded warrants in lieu thereof). Each share of common stock (or pre-funded warrant) is being sold at a public offering price of $1.00 per share (inclusive of the pre-funded warrant exercise price) for gross proceeds to Tharimmune of $10,000,000. All of the shares of common stock and pre-funded warrants are being offered by the company. In addition, Tharimmune granted the underwriters a 45-day option to…

Continue Reading

WednesdayNov 29, 2023 2:17 pm

BioMedNewsBreaks – Branded Legacy Inc. (BLEG) Commences Buyback of 1M Preferred Class D Shares

Branded Legacy (OTC: BLEG), a pioneer in the biotechnology and wellness industries, announced its strategic decision to buy back and retire 1,000,000 Preferred Class D Shares. The significant move protects against a conversion ratio of 1 Preferred Class D Share to 100 Common Unrestricted shares, marking a pivotal step in enhancing shareholder value and simplifying Branded Legacy’s share structure by preventing these shares from entering the market. “The buyback and retirement of these Preferred Class D Shares is a strategic move to reinforce our shareholders’ value by preventing dilution,” said Branded Legacy CEO David Oswald. “We are committed to enhancing…

Continue Reading

WednesdayNov 29, 2023 1:34 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Maturity Extension of EIB Finance Facility

Scinai Immunotherapeutics (NASDAQ: SCNI) today announced the execution of a formal amendment to its finance contract with the European Investment Bank (“EIB”). According to the announcement, the amendment extends the maturity date of the contract by four years from Dec. 31, 2027, to Dec. 31, 2031. “I thank the EIB for their ongoing support and cooperation. As the lending arm of the European Union, the EIB’s mission includes providing financing to support medical research and improve health care, and to do so in a manner that provides innovative young companies not only with required resources but also sufficient time to…

Continue Reading

TuesdayNov 28, 2023 12:24 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Issues update on GBB Drink Lab Inc. Litigation and Safety Shot

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions. The company has issued a statement as an update regarding its litigation with GBB Drink Lab Inc. previously referenced at: FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. (NASDAQ: JUPW). In May of this year, GBB filed a lawsuit against FSD Pharma alleging a material breach of a mutual nondisclosure agreement and trade secret misappropriation. FSD Pharma has categorically denied these allegations and filed a motion to dismiss the lawsuit, which is…

Continue Reading

MondayNov 27, 2023 1:43 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in Goldman Small Cap Research Report, Receives Approval for Celly Nu Plan of Arrangement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is spotlighted in a recent report released by Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors. The new report notes that through its wholly owned subsidiary, Lucid Psycheceuticals Inc., FSD is working to develop its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The report also mentions that FSD is working to research and develop UNBUZZD(TM),…

Continue Reading

MondayNov 27, 2023 1:19 pm

BioMedNewsBreaks – Safety Shot (NASDAQ: SHOT) Begins Scientific Study, Hires Securities Litigation Attorney

Safety Shot (NASDAQ: SHOT), a wellness and functional beverage company, has begun a double-blind, placebo-controlled clinical trial designed to study and evaluate the effects of its flagship product, Safety Shot, on blood and breath alcohol levels. According to the announcement, the company is committed to the scientific development of Safety Shot, the first patented beverage designed to reduce blood alcohol content and boost clarity in order to help people feel better faster. The exclusive nutraceutical functional beverage accelerates the body’s breakdown of alcohol while aiding in recovery and rehydration. The company anticipated having topline data by first quarter 2024. “Recent…

Continue Reading

MondayNov 27, 2023 12:37 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Closes on Public Offering Reaching Estimated $7M

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has closed its previously announced public offering. The offering was comprised of 5,384,615 shares of common stock (or common stock equivalents in lieu thereof) and warrants; the shares were offered at $1.30 per share (or common stock equivalent in lieu thereof) and accompanying warrant. According to the announcement, the warrants also had an exercise price of $1.30 per share, as well as being exercisable immediately upon issuance; the warrants will expire five years after the initial exercise date. The company noted that total gross proceeds for the…

Continue Reading

WednesdayNov 22, 2023 3:22 pm

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Featured Guest in Recent Proactive Interview

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, was featured in a recent Proactive interview. Mark Dybul, CEO of Renovaro, joined host Steve Darling to talk about the company and its achievements and potential. Specifically, the two talked about the company’s recent signing of a definitive agreement to merge with GEDiCube, a United-Kingdom-based medical artificial intelligence (“AI”) company renowned for its contributions to the early detection and remission of cancer, as well as expedited drug discovery. During the interview, Dybul discussed the plan to rebrand GEDiCube…

Continue Reading

WednesdayNov 22, 2023 2:56 pm

BioMedNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) Issues Warning to Shareholders

Safety Shot (NASDAQ: SHOT) today announced that it has come to its attention that there are several disclosed short sellers publishing malicious defamatory, inaccurate articles about Safety Shot and its management in a willful attempt to scare SHOT investors out of their positions in hopes of getting them to sell their shares so they can then buy at a lower cost to cover their disclosed short position. According to the announcement, several groups are currently being sued in federal court for publishing these fraudulent articles on other companies, and Safety Shot will be preparing a similar lawsuit against these Cayman…

Continue Reading